October 2026
TMPRSS2 inhibitor COVID-19 outcomes
StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Ansarin (RCT)91%0.09 · 0.01–1.59death0/395/39bromhexine
Ansarin (RCT)89%0.11 · 0.01–0.84ventilation1/399/39bromhexine
Ansarin (RCT)82%0.18 · 0.04–0.77ICU2/3911/39bromhexine
Sagent P.. (DB RCT)−152%2.52 · 0.10–61.33death1/1940/101CAMELOTcamostat
Sagent P.. (DB RCT)13%0.87 · 0.32–2.32progression10/1946/101CAMELOTcamostat
Sagent P.. (DB RCT)16%0.84 · 0.60–1.18viral+58/19436/101CAMELOTcamostat
Parsonnet (DB RCT)−392%4.92 · 0.25–97.48progression2/250/24COPS-2003camostat
Parsonnet (DB RCT)35%0.65 · 0.32–1.33no recov.25 (n)24 (n)COPS-2003camostat
Parsonnet (DB RCT)86%0.14 · 0.01–2.58misc.0/253/24COPS-2003camostat
Parsonnet (DB RCT)41%0.59 · 0.24–1.43viral+25 (n)24 (n)COPS-2003camostat
Chupp (DB RCT)0%1.00 · 0.07–15.36hosp.1/351/35camostat
Chupp (DB RCT)37%0.63 · 0.36–1.09no recov.12/3519/35camostat
Dhaliwal (RCT)14%0.86 · 0.17–4.45hosp.2/143/18SPIKE-1camostat
Kinoshita (DB RCT)67%0.33 · 0.01–8.05progression0/741/74CANDLEcamostat
Kinoshita (DB RCT)50%0.50 · 0.16–1.59oxygen4/748/74CANDLEcamostat
Kinoshita (DB RCT)−1%1.01 · 0.72–1.42no recov.30/5329/52CANDLEcamostat
Kinoshita (DB RCT)−1%1.01 · 0.71–1.67viral+78 (n)77 (n)CANDLEcamostat
Tobback (RCT)−36%1.36 · 0.15–12.58hosp.3/661/30camostat
Tobback (RCT)8%0.92 · 0.46–1.87no recov.61 (n)29 (n)camostat
Vila Méndez (RCT)67%0.33 · 0.01–7.94oxygen0/981/93bromhexine
Vila Méndez (RCT)67%0.33 · 0.01–7.94hosp.0/981/93bromhexine
Vila Méndez (RCT)71%0.29 · 0.03–2.68no recov.1/523/45bromhexine
Vila Méndez (RCT)−187%2.87 · 0.12–68.64no recov.1/520/45bromhexine
Vila Méndez (RCT)−7%1.07 · 0.64–1.77viral load98 (n)93 (n)bromhexine
Vila Méndez (RCT)17%0.83 · 0.41–1.66viral load98 (n)93 (n)bromhexine
Vila Méndez (RCT)−41%1.41 · 0.71–2.80viral load98 (n)93 (n)bromhexine
Vila Méndez (RCT)13%0.87 · 0.68–1.11viral+52/9857/93bromhexine
Vila Méndez (RCT)−14%1.14 · 0.94–1.37viral+73/9861/93bromhexine
Kim (DB RCT)8%0.92 · 0.70–1.19no recov.161 (n)162 (n)camostat
Kim (DB RCT)25%0.75 · 0.43–1.30no recov.109 (n)104 (n)camostat
Kim (DB RCT)46%0.54 · 0.28–1.03no recov.77 (n)78 (n)camostat
Kim (DB RCT)40%0.60 · 0.26–1.33no recov.109 (n)104 (n)camostat
Kim (DB RCT)58%0.42 · 0.17–1.03no recov.77 (n)78 (n)camostat
Okugawa (RCT)33%0.67 · 0.50–0.89viral load19 (n)10 (n)nafamostat
Okugawa (RCT)60%0.40 · 0.19–0.83viral load19 (n)10 (n)nafamostat
Tare (DB RCT)33%0.67 · 0.22–2.09no recov.4/195/16DAWNcamostat
Tare (DB RCT)23%0.77 · 0.48–1.24no recov.11/1912/16DAWNcamostat
Li (RCT)75%0.25 · 0.06–1.00no disch.2/124/6bromhexine
Li (RCT)50%0.50 · 0.09–2.73oxygen2/122/6bromhexine
Mareev (RCT)11%0.89 · 0.65–1.22no recov.33 (n)33 (n)bromhexine CT2
Mareev (RCT)39%0.61 · 0.14–0.97no recov.14/2420/21bromhexine CT2
Mareev (RCT)8%0.92 · 0.77–1.09hosp. time33 (n)33 (n)bromhexine CT2
Mareev (RCT)87%0.13 · 0.01–2.25viral+0/173/13bromhexine CT2
Tolouian (RCT)76%0.24 · 0.01–8.03death48 (n)52 (n)bromhexine
Tolouian (RCT)76%0.24 · 0.01–7.69no improv.48 (n)52 (n)bromhexine
Tolouian (RCT)−75%1.75 · 1.13–2.71viral+29/4818/52bromhexine
Sakr (PSM)69%0.31 · 0.15–0.60death6/6118/61camostat
Sakr (PSM)10%0.90 · 0.39–2.06ventilation9/6110/61camostat
Sakr (PSM)−17%1.17 · 0.85–1.61hosp. time61 (n)61 (n)camostat
Gunst (DB RCT)18%0.82 · 0.24–2.79death8/1374/68CamoCO-19camostat
Gunst (DB RCT)31%0.69 · 0.14–3.44ventilation13/1373/68CamoCO-19camostat
Gunst (DB RCT)20%0.80 · 0.34–1.91ICU14/1378/68CamoCO-19camostat
Gunst (DB RCT)15%0.85 · 0.62–1.15no recov.137 (n)68 (n)CamoCO-19camostat
Zhuravel (RCT)76%0.24 · 0.03–2.08death1/524/50nafamostat
Zhuravel (RCT)42%0.58 · 0.23–1.47no improv.6/5210/50nafamostat
Zhuravel (RCT)42%0.58 · 0.23–1.47no recov.6/5210/50nafamostat
Zhuravel (RCT)41%0.59 · 0.32–1.09no recov.52 (n)50 (n)nafamostat
Inokuchi−27%1.27 · 0.61–2.64death121 (n)15,738 (n)nafamostat
Quinn (RCT)0%1.00 · 0.23–4.40death3/213/21DEFINEnafamostat
Quinn (RCT)−48%1.48 · 0.81–2.69hosp. time21 (n)21 (n)DEFINEnafamostat
Terada (RCT)54%0.46 · 0.04–4.92death1/612/56camostat CT2
Terada (RCT)8%0.92 · 0.37–2.28progression8/618/56camostat CT2
Terada (RCT)40%0.60 · 0.37–0.97no disch.61 (n)56 (n)camostat CT2
Karolyi (RCT)72%0.28 · 0.06–1.33death2/1017/100ACOVACTcamostat OT1
Karolyi (RCT)70%0.30 · 0.10–0.90ventilation4/10113/100ACOVACTcamostat OT1
Karolyi (RCT)60%0.40 · 0.16–0.98death/int.6/10115/100ACOVACTcamostat OT1
Karolyi (RCT)18%0.82 · 0.71–0.94recov. time101 (n)100 (n)ACOVACTcamostat OT1
Karolyi (RCT)8%0.92 · 0.86–0.99recov. time101 (n)100 (n)ACOVACTcamostat OT1
Karolyi (RCT)14%0.86 · 0.75–0.98hosp. time101 (n)100 (n)ACOVACTcamostat OT1
Soma80%0.20 · 0.01–4.11death0/312/33nafamostat
Soma−6%1.06 · 0.51–2.20severe case10/3110/33nafamostat
Jilg (RCT)1%0.99 · 0.06–15.63death1/1061/105ACTIV-2camostat
Jilg (RCT)−198%2.98 · 0.12–72.39death1/1090/107ACTIV-2camostat
Jilg (RCT)−18%1.18 · 0.37–3.74hosp.6/1095/107ACTIV-2camostat
Jilg (RCT)10%0.90 · 0.79–1.02progression85/10993/107ACTIV-2camostat
Jilg (RCT)13%0.87 · 0.46–1.64no recov.15/10917/107ACTIV-2camostat
Jilg (RCT)14%0.86 · 0.56–1.30no recov.109 (n)107 (n)ACTIV-2camostat
Jilg (RCT)14%0.86 · 0.21–3.47no recov.109 (n)107 (n)ACTIV-2camostat
Jilg (RCT)8%0.92 · 0.54–1.56no recov.109 (n)107 (n)ACTIV-2camostat
Seccia (DB RCT)67%0.33 · 0.02–7.02death0/71/7RACONAnafamostat
Seccia (DB RCT)20%0.80 · 0.36–1.77no recov.4/75/7RACONAnafamostat
Morpeth (RCT)55%0.45 · 0.14–1.42ventilation4/828/73ASCOTnafamostat
Morpeth (RCT)57%0.43 · 0.13–1.29progression4/828/73ASCOTnafamostat
Morpeth (RCT)28%0.72 · 0.36–1.45no recov.82 (n)73 (n)ASCOTnafamostat
Bryce (DB RCT)25%0.75 · 0.18–3.18death3/504/50RECOVERcamostat
Huh−14%1.14 · 0.31–4.18casescase-control studycamostat
Mikhaylov (RCT)80%0.20 · 0.01–3.97hosp.0/252/25bromhexine
Mikhaylov (RCT)91%0.09 · 0.01–1.56symp. case0/255/25bromhexine
Mikhaylov (RCT)71%0.29 · 0.07–1.24cases2/257/25bromhexine
Tolouian (DB RCT)33%0.67 · 0.04–10.46death0/1871/185bromhexine
Tolouian (DB RCT)70%0.30 · 0.05–1.78hosp.1/1876/185bromhexine
Tolouian (DB RCT)53%0.47 · 0.25–0.87symp. case16/18734/185bromhexine
Tolouian (DB RCT)50%0.50 · 0.24–0.99cases13/18726/185bromhexine
00.511.52+